Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Frazier Healthcare Partners Adds Highly Experienced Pharmaceutical Executive to Growth Buyout Team

September 28, 2021 GMT

SEATTLE--(BUSINESS WIRE)--Sep 28, 2021--

Frazier Healthcare Partners, a leading private equity and venture capital firm focused exclusively on the healthcare industry, is pleased to announce that Amanda Bosse has joined the firm’s Growth Buyout team as an Executive in Residence. Ms. Bosse will work alongside the firm to develop and execute investment strategies focused on differentiated outsourced pharmaceutical contract manufacturing and scientific services enabling advanced therapies. In this role, Ms. Bosse will focus on the sourcing, diligence, and leadership of a new platform that enables the next generation of life sciences products and personalized medicine.

Ben Magnano, Frazier Managing Partner, said: “We are thrilled that Amanda has chosen to join Frazier as the firm looks to continue its investment focus in the outsourced pharmaceutical services sector. Her experience as a global business leader in both drug development and commercial manufacturing will greatly enhance our investing efforts along the entire pharmaceutical development and manufacturing continuum. Amanda is a great fit with our values and culture, and we are fortunate to have her on the Frazier team.”


Amanda Bosse said: “I am excited to be joining Frazier and continuing to foster a passion area - enabling customers to bring medicines to market with speed and the highest quality possible. We will focus on platforms that offer differentiated service, deep technical expertise, and excellent service for customers. I look forward to partnering with Frazier on a platform.”

Ms. Bosse brings over 20 years of experience in the pharmaceutical products and services industry. Most recently, Ms. Bosse served as the President of Drug Product Services for Thermo Fisher Scientific, where she held responsibility for drug product development and commercial manufacturing of oral solid and sterile injectable drug products. Prior to her tenure at Thermo Fisher Scientific, she held several leadership roles of increasing responsibility across pharmaceutical development, operations, strategy and innovation, as well as commercial functions for Patheon Pharmaceuticals, a pharma services solution provider for drug development, clinical trial logistics, and commercial manufacturing. Ms. Bosse holds a Bachelor of Science in Chemical Engineering from the University of Cincinnati and Advanced Management Executive Program from Harvard Business School. Ms. Bosse is actively involved in the community and various philanthropic institutions with a focus on helping children and families in need. Additionally, she serves as an active mentor in the development and expansion of female leadership.

About Frazier Healthcare Partners:


Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With over $6 billion in total capital raised, Frazier has invested in more than 200 companies with transaction types ranging from buyouts of profitable healthcare services companies to venture capital and company creation. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier has offices in Seattle, WA, and Menlo Park, CA, and invests broadly across the U.S., Canada, and Europe.

For more information about Frazier Healthcare Partners, visit

View source version on

CONTACT: Frazier Healthcare Partners

Carol Eckert, VP of Investor Relations

Phone: 206.621.7200



SOURCE: Frazier Healthcare Partners

Copyright Business Wire 2021.

PUB: 09/28/2021 08:00 AM/DISC: 09/28/2021 08:02 AM